The enhanced anti-tumor immunity in immunogenic tumors might be ascribed into the inhibition of PTP1B/PTPN2 in T cells, whereas in chilly tumors, Compound-182 elicited immediate outcomes on the two tumor cells and T cells. Importantly, treatment with Compound-182 rendered in any other case resistant tumors sensitive to ?-PD-1 therapy. Our results b